Business Context and Reporting Period
This Form 8-K Current Report was filed by NewAmsterdam Pharma Company N.V. on July 16, 2024, regarding corporate governance changes effective immediately on that date. The company is incorporated in The Netherlands and its ordinary shares and warrants trade on The Nasdaq Stock Market LLC under the symbols "NAMS" and "NAMSW," respectively.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on personnel changes and related compensation arrangements.
Material Changes
- Board Resignation: Sander Slootweg resigned as a member of the Board of Directors effective July 16, 2024. The resignation was not the result of any disagreement with the Company, its management, or the Board.
- Board Appointments: The Board appointed Wouter Joustra and Mark C. McKenna as temporary non-executive directors effective July 16, 2024, pending formal appointment at the next general meeting of shareholders.
- Committee Assignments: Mark C. McKenna was appointed to serve on the Audit Committee and Compensation Committee.
- Compensation Grant: Mark C. McKenna was granted options to subscribe for 72,500 ordinary shares at an exercise price of $18.81 per share. Vesting begins on the first anniversary of the start date (33%) followed by equal monthly installments over two years.
Outlook, Risks, and Unusual Items
The filing notes that Mr. Joustra serves as a General Partner at Forbion, an investor that participated in a secondary offering of the Company's shares in June 2023. The Company did not receive proceeds from that secondary offering. No new risks, contingencies, or unusual items were disclosed in this report beyond the standard indemnification agreements for directors.
Investor Verification Checklist
- Verify the formal appointment of Wouter Joustra and Mark C. McKenna at the next general meeting of shareholders.
- Review the vesting schedule and exercise price ($18.81) of the 72,500 options granted to Mark C. McKenna.
- Confirm the independence status of the new directors under Nasdaq listing standards.
- Check for any potential conflicts of interest given Mr. Joustra's role at Forbion, a participant in the Company's prior secondary offering.